first week of tirzepatide caused roughly half as many patients to stop treatment because gastrointestinal side effects as semaglutide. In the major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide How Fast Tirzepatide Works for

[3] A two-year study published in 2022 examining semaglutide treatment in overweight or obese users, which found over 82% of semaglutide users experienced mild to moderate gastrointestinal adverse events compared with only just over half of non-users

Therefore, aggressive diuretic use and massive fluid restriction may be effective at reducing body weight for a short time, despite concerns of electrolyte imbalance and blood pressure drops during treatment

doi:10.1016/j.diabres.2015.12.022 92

European Journal of Applied Physiology, 73, 434-439

Emerging roles of ferroptosis in the tumor immune landscape: from danger signals to anti-tumor immunity

FDA statement on enforcement priorities regarding compounded GLP-1 receptor agonist products [Press release]